A research team unveiled an intelligent design framework for adeno‑associated virus (AAV) vectors that dynamically respond to tumor microenvironment cues to improve targeting and intratumoral infiltration. The paper describes engineering strategies that tune AAV tropism and expression in response to tumor‑specific signals, addressing longstanding delivery barriers for viral gene therapies. The approach could accelerate translational programs that require tumor‑restricted gene expression and reduce off‑target toxicity, but will require rigorous preclinical safety validation and manufacturability assessment.